PeptideDB

Purmorphamine

CAS: 483367-10-8 F: C31H32N6O2 W: 520.62

Purmorphamine is a smoothened/Smo receptor agonist with an EC50 of 1 μM.
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Purmorphamine is a smoothened/Smo receptor agonist with an EC50 of 1 μM.
Target IC50: 1.5 μM (Smoothened)
Invitro Purmorphamine (10, 20 μM) in combination with sirolimus significantly decreases cell numbers according to the MTT assay. Purmorphamine induces up-regulation of alkaline phosphatase activity and expression of RUNX-2 at day 14. Up-regulation of osteocalcin is detected at the 3 and 5 μM doses of purmorphamine on day 14 post-induction. Matrix mineralization remains unchanged in the presence or absence of purmorphamine[1]. Purmorphamine induces STAT3 phosphorylation in mouse ES cell line ES14 and mesenchymal stem cell line C3H10T1/2[2]. Purmorphamine up-regulates the expressionof markers of the osteoblast phenotype-ALP activity and bone-like nodule formationd-in human bonemarrow mesenchymal cells[3].
Name Purmorphamine
CAS 483367-10-8
Formula C31H32N6O2
Molar Mass 520.62
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Reference [1]. F. Faghihia, et al. The effect of purmorphamine and sirolimus on osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. Biomedicine & Pharmacotherapy. 2013, 67(1): 31-38. [2]. Gu D, et al. A role for transcription factor STAT3 signaling in oncogene smoothened-driven carcinogenesis. J Biol Chem. 2012 Nov 2;287(45):38356-66. [3]. Beloti MM, et al. Purmorphamine enhances osteogenic activity of human osteoblasts derived from bone marrow mesenchymal cells. Cell Biol Int. 2005 Jul;29(7):537-41.